Why the study?
Data on aspirin prophylaxis for cardiovascular event prevention in kidney transplant recipients are sparse, with major concerns including bleeding and nephrotoxicity.
Does aspirin prevent cardiovascular events in kidney transplant recipients?
Does aspirin prevent cardiovascular events in kidney transplant recipients?
This review highlights the sparse evidence and ongoing debate regarding the risks (bleeding, nephrotoxicity) and benefits of aspirin for primary cardiovascular prophylaxis in kidney transplant recipients.
Answers are grounded in this paper and cite their sources.
Evidence too limited to support aspirin for primary CV prophylaxis in kidney transplant recipients; leaves open need for dedicated RCTs.
Kidney transplant recipients have traditional and nontraditional risk factors which can lead to coronary artery disease and sudden death with a functional graft loss. Aspirin has been used traditionally for prevention of cardiovascular and cerebrovascular accidents. It has beneficial effects in secondary prevention of cardiovascular events in general population. Its use for primary prophylaxis is still disputed. Bleeding and theoretical risk of nephrotoxicity are the major concerns about its use. The data on aspirin in kidney transplant population is sparse. This review will focus on various pros and cons of aspirin use for prevention of cardiovascular events in kidney transplant recipients and a way forward.
No takes yet. Share an insight, caveat, or question.
Khalil et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: